Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Seymour, JF, Kipps, TJ, Eichhorst, B et al. (17 more authors) (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 378 (12). pp. 1107-1120. ISSN 0028-4793

Abstract

Metadata

Authors/Creators:
  • Seymour, JF
  • Kipps, TJ
  • Eichhorst, B
  • Hillmen, P ORCID logo https://orcid.org/0000-0001-5617-4403
  • D’Rozario, J
  • Assouline, S
  • Owen, C
  • Gerecitano, J
  • Robak, T
  • De la Serna, J
  • Jaeger, U
  • Cartron, G
  • Montillo, M
  • Humerickhouse, R
  • Punnoose, EA
  • Li, Y
  • Boyer, M
  • Humphrey, K
  • Mobasher, M
  • Kater, AP
Copyright, Publisher and Additional Information: © 2018 Massachusetts Medical Society. From Seymour, JF, Kipps, TJ, Eichhorst, B et al. (17 more authors) (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 378 (12). pp. 1107-1120. ISSN 0028-4793. Reprinted with permission.
Dates:
  • Published (online): 22 March 2018
  • Published: 22 March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Jan 2019 16:20
Last Modified: 07 Jan 2019 16:20
Status: Published
Publisher: Massachusetts Medical Society
Identification Number: https://doi.org/10.1056/NEJMoa1713976

Share / Export

Statistics